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ABSTRACT Infections caused by highly successful clones of hospital-associated methicillin-resistant Staphylococcus aureus (HA-
MRSA) are a major public health burden. The globally dominant sequence type 239 (ST239) HA-MRSA clone has persisted in the
health care setting for decades, but the basis of its success has not been identified. Taking a collection of 123 ST239 isolates span-
ning 32 years, we have used population-based functional genomics to investigate the evolution of this highly persistent and suc-
cessful clone. Phylogenetic reconstruction and populationmodeling uncovered a previously unrecognized distinct clade of
ST239 that was introduced into Australia from Asia and has perpetuated the epidemic in this region. Functional analysis demon-
strated attenuated virulence and enhanced resistance to last-line antimicrobials, the result of two different phenomena, adaptive
evolution within the original Australian ST239 clade and the introduction of a new clade displaying shifts in both phenotypes.
The genetic diversity between the clades allowedus to employ genome-wide association testing and identifymutations in other essen-
tial regulatory systems, includingwalKR, that significantly associatewith andmay explain these key phenotypes. The phenotypic con-
vergence of two independently evolving ST239 clades highlights the very strong selective pressures acting onHA-MRSA, showing that
hospital environments have favored the accumulation ofmutations in essentialMRSAgenes that increase resistance to antimicrobials,
attenuate virulence, and promote persistence in the health care environment. Combinations of comparative genomics and careful phe-
notypicmeasurements of longitudinal collections of clinical isolates are giving us the knowledge to intelligently address the impact of
current and future antibiotic usage policies and practices onhospital pathogens globally.
IMPORTANCE Methicillin-resistant Staphylococcus aureus (MRSA) is responsible for innumerable drug-resistant health care-
associated infections globally. This study, the first to investigate the evolutionary response of hospital-associatedMRSA (HA-
MRSA) over many decades, demonstrates howMRSA can persist in a region through the reintroduction of a previously unrecog-
nized distinct clade. This study also demonstrates the crucial adaptive responses of HA-MRSA to the highly selective
environment of the health care system, the evolution of MRSA isolates to even higher levels of antibiotic resistance at the cost of
attenuated virulence. However, in vivo persistence is maintained, resulting in a clone of HA-MRSA able to resist almost all anti-
microbial agents and still cause invasive disease in the heavily compromised hosts found in modern health care settings.
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Staphylococcus aureus is one of themost common and problem-atic causes of infectious disease in humans. The emergence and
spread of epidemic drug-resistant S. aureus clones have often been
referred to as a wave-like phenomenon, with the first wave repre-
senting the development of penicillin-resistant S. aureus, the sec-
ond wave representing that of methicillin-resistant S. aureus
(MRSA), and the third and fourth waves representing the es-
tablishment of the highly successful hospital-associated MRSA
(HA-MRSA) lineages that are encountered today and the ap-
pearance of genetically distinct MRSA clones in the commu-
nity, respectively (1).
Genomic studies are providing new insights into the popula-
tion structure of S. aureus, MRSA in particular, and have shown
that the majority of HA-MRSA infections are the result of a small
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number of dominant, typically multidrug-resistant, clones that
rarely cause disease outside the hospital setting (2, 3). One of the
most successful and persistent clones is the globally dispersed,
multidrug-resistant multilocus sequence type 239 (ST239), a nat-
urally occurring hybrid having originated from a large recombi-
nation event involving descendants of the twomajor staphylococ-
cal lineages, clonal complexes 8 and 30 (4). The earliest reports of
MRSA ST239 date back to the late 1970s in Australia (5), the
United Kingdom (6), and the United States (7). However,
multidrug-resistant MRSA belonging to phage group III and pos-
sibly representing ST239 has been isolated in Australia since the
1960s (8). From the 1980s, ST239 had been reported as the caus-
ative agent of numerous epidemics in health care institutions
worldwide; the number of regional names given to the ST239
clone attests to its success. These include, but are not limited to,
the Brazilian, British epidemic (EMRSA-1, -4, -7, -9 and -11),
Canadian epidemic (CMRSA-3), Hungarian, Portuguese, Nan-
jing/Taipei, Vienna, and Eastern Australian epidemic (EMRSA-
Aus-2 and -Aus-3) clones.
Recent studies have explored the global population structure
(9–11) and phylogeography (12) of ST239, as well as the role of
recombination and the contribution of other mobile genetic ele-
ments to the spread and survival of this clone (11, 13, 14). How-
ever, the mechanisms underlying the successful adaptation and
survival of ST239 MRSA within the health care environment, in
particular, the phenotypic evolution of this clone, are poorly un-
derstood. There is a high prevalence of reduced glycopeptide sus-
ceptibility among HA-MRSA isolates in Australia (15), where
ST239 has been a dominant MRSA clone for more than 30 years
(16). Additionally, a recent study of S. aureus bacteremia isolates
from Australia demonstrated higher vancomycinMICs for ST239
isolates than for other clones (17), suggesting that the ST239 clone
may be adapted to enhanced antimicrobial resistance.
Using both genomic and integrated phenotypic approaches,
we have explored the evolutionary dynamics of ST239 MRSA in
Australia, revealing that two clades of this highly successful clone
have evolved independently in our region, both contributing to
enhanced antibiotic resistance and attenuated virulence driven by
mutations in highly conserved essential regulatory genes. This
work provides an in-depth insight into the persistence and evolu-
tion of HA-MRSA and highlights a bacterial population level re-
sponse to the long-term and widespread use of antibiotics that is
driving even higher levels of resistance.
RESULTS AND DISCUSSION
Global and regional phylogeny of ST239 MRSA. To recover the
population structure of Australian ST239 MRSA, as well as ex-
plore the evolution of this sequence type within a global phylog-
eny, we collected 87 ST239 isolates fromhealth care institutions in
Australia and New Zealand between 1980 and 2012. The majority
of these isolates (n 69) were recovered from cases of bacteremia
or tissue infection.We supplemented this collectionwith the pub-
licly available whole-genome sequence reads of a further 35 inter-
national ST239 isolates from the collection of Harris et al. (10).
These additional isolates were recovered fromAsia, Europe, South
America, and North America between 1993 and 2007 and repre-
sented the phylogenetic diversity observed in their population
model. Relevant isolate demographics and a summary of the se-
quencing results are available in Data Set S1 in the supplemental
material.
Alignment of whole-genome sequence reads for all 123 isolates
with reference ST239 isolate TW20 identified 2,716 core genome
single nucleotide polymorphisms (SNPs). A maximum clade
credibility (MCC) tree generated from these core genome SNPs is
presented in Fig. 1A. The population structure proposed by the
MCC tree is robust because of the strong branch support and the
distinct grouping of isolates with shared geographic source creat-
ing regional clades, a finding consistent with previous ST239 phy-
logenetic models. These clades reflect the capacity of ST239 to
undergo extensive local expansion but limited intercontinental
transmission (9–11).
The Australian ST239 isolates followed a similar pattern,
grouping into two distinct clades on the MCC tree (annotated as
Clades 1 and 2). The separation of these clades indicates the indi-
vidual evolutionary paths along which they have developed, while
the distance between them suggests that their core genomes are as
different from each other as those of other continental clades. This
reveals that ST239MRSAhas undergone concurrent but indepen-
dent spread twice within Australia. Clade 1 isolates represented all
of the regions sampled and 27 of the 32 years in the temporal span
of the collection (1980 to 2007). Conversely, Clade 2 isolates were
considerably less diverse; all were recovered in the Australian state
of Victoria, the earliest of which was isolated in 2001. The differ-
ence in the demographic diversity of these two clades is consistent
with Clade 1 being the original Australian ST239 clade and Clade
2 representing a more recent, previously unrecognized, reintro-
duction of ST239 into the Australian region. The more recent
common ancestor shared by Clade 2 and the predominately Asian
isolates, combined with the high posterior probability of major
nodes connecting these groups, is highly supportive of an inter-
continental transmission event betweenAsia andAustralia, result-
ing in the local establishment of Clade 2. Furthermore, the only
four Australian isolates that did not group with either large clade
were located in a small, distinct clade close to Clade 2 and the
Asian isolates. All four isolates were recovered in the Australian
state of Victoria in 2000 and 2001, suggesting that more than one
intercontinental transmission event may have occurred between
the neighboring continents of Australia and Asia.
Genomic characterization of Australian ST239 MRSA. To
further investigate themolecular differences between the twoAus-
tralian ST239 clades, as well as understand the impact of the in-
troduction of Clade 2, we estimated the rate of nucleotide substi-
tution, modeled the population size over time, and examined the
conservation of protein coding sequences (CDS) among the
clades.
Nucleotide substitution rate. An initial global ST239 phylog-
eny, inferred by maximum-likelihood (ML) phylogenetic analy-
sis, demonstrated a temporal gradient when rooted with a non-
ST239 outgroup. This was further supported by the strong
correlation between the branch length and the year of isolation
(R2 0.8261, Fig. 1B). A comparison of the MCC and ML topol-
ogies is provided in Fig. S1 in the supplemental material. The
Bayesian analysis estimated the mean rate of nucleotide substitu-
tions for the ST239 clone at 1.6 106 substitutions per site per
year (ss1 year1), with a 95% highest posterior density (HPD)
interval of 1.2  106 to 2.0  106 ss1 year1. This rate is
marginally slower than previous estimates of 3.3  106 (95%
confidence interval, 2.5  106 to 4.0  106) ss1 year1 (10),
and 3.4  106 (95% HPD interval, 2.7  106 to 4.1  106)
ss1 year1 (12). Our estimate places the emergence of the ST239
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FIG 1 Global phylogeny and molecular clock of ST239 MRSA. (A) MCC tree, generated in BEAST v1.7.5 from 2,716 SNPs in the core genome of 123 isolates,
illustrating the global phylogeny of ST239 MRSA. Branches are colored to reflect statistical support; those possessing a posterior probability of95% are red.
Major branches with95% support are annotated with their respective posterior probabilities. Branch annotations provide isolate names, countries, and years
of recovery and are colored to reflect the source continents (yellow, Australasia; red, Europe; green, South America; blue, Asia). For Australian isolates, the state
of origin is indicated by a colored box (see key). Australian clades are shaded and annotated as Clade 1 and Clade 2. (B) Root-to-tip divergence graph illustrating
the strong correlation between year of recovery and branch length, estimated from an ML phylogenetic model. Data points representing Clade 1 and 2 isolates
are blue and red, respectively. Trend lines are included for all of the data points (black), Clade 1 (blue), and Clade 2 (red) and have been extrapolated to estimate
emergence dates.
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clone in 1946 (95%HPD interval, 1885 to 1973). To ascertain the
mutation rate and emergence date of each Australian clade, the
Bayesian analysis was repeated by testing Clades 1 and 2 indepen-
dently. Clade 1 was found to mutate at a mean rate of 9.2 107
(95% HPD interval, 5.8  107 to 1.3  106) ss1 year1, and
Clade 2 was found to mutate at a mean rate of 1.3  106 (95%
HPD interval, 6.5 107 to 2.0 106) ss1 year1. From this,
we estimated that Clade 1 emerged in 1962 (95% HPD interval,
1919 to 1981) and Clade 2 emerged in 1986 (95% HPD interval,
1954 to 1998).
Population size. To determine whether Clade 2 had contrib-
uted to the persistence of ST239 in the Australian health care en-
vironment, a Bayesian Skyline model was employed to estimate
changes in the effective population size (EPS) of each clade over
time (18). The EPS is estimated from the observed nucleotide
variation (genetic diversity) in relation to the mutation rate and
can be used to infer changes in the size of a population. These
models, illustrated in Fig. 2A, suggested a steady increase in the
EPS of Clade 1 from the early 1980s to the late 1990s, followed by
a nearly 10-fold decrease over the next 10 years. This result was
highly consistent with the reported dominance of the ST239 clone
among HA-MRSA isolates in Australia over the last 30 years, as
well as the subsequent decrease since 2005 (16). Intriguingly, the
EPS of Clade 2 appeared stable throughout the modeled time
frame of 2000 to 2012 and could be maintaining the ST239 pop-
ulation in Australia. This may partly explain why the ST239 clone
still represents nearly half ofHA-MRSA strains encountered in the
health care environment nationally and 70% of those in the state
of Victoria, where Clade 2 appears to be focused (19).
Gene content variation. To investigate larger genomic differ-
ences between the two clades, protein ortholog clustering was
used to examine the variation in gene presence or absence. Amul-
tidimensional scaling (MDS) representation of these data illus-
trated discrete, clade-specific clustering (Fig. 2B), further high-
lighting the genomic divergence in Australian ST239 MRSA. A
total of 67 orthologs were identified that differentiated the two
clades, each being detected in aminimumof 50%of one clade and
absent from all of the isolates of the other clade. It was noted that
eight clade 1 isolates, all recovered in the early 1980s, appeared to
share more protein orthologs with Clade 2, as indicated by their
location in the MDS plot, than any other Clade 1 isolates. When
these eight isolates are excluded, the number of orthologs that
differentiate the two clades increased to 209. Of these, 123 (59%)
were associated with the three prophages identified in TW20
(Sa1, Sa3, and Sa-like). Orthologs associated with these
prophages were only identified in Clade 2 isolates and the eight
Clade 1 isolates. The Sa-like prophage is of interest in the evo-
lution of the ST239 clone because it carries the recently identified
virulence determinant sasX. Located at the 3= end of theSP-like
prophage, sasX encodes a small, surface-anchored protein that
enhances nasal colonization, abscess formation, and tissue dam-
age in the lungs during respiratory infection and has been impli-
cated in the rapid spread of ST239 throughout Asia (13). Li et al.
reported that the prevalence of sasX among ST239 MRSA in Asia
increased substantially between 2003 and 2011, suggesting the
preferential uptake of this mobile element. Local alignment iden-
tified sasX in all of the Clade 2 isolates, as well as the eight clade 1
isolates described above. While this may suggest a role for sasX in
the evolution of Clade 2, its absence from most Clade 1 isolates
indicates that it has not been transferred between the two clades.
Furthermore, its presence among only a small number of early
Clade 1 isolates suggests that it has been selectively lost, raising
questions about the role of sasX in the evolution of ST239 MRSA
in Australia. Nonetheless, the conservation of sasX among Clade 2
isolates is further evidence that this clade originated in Asia.
Collectively, these genomic analyses reveal that while both
clades exist and have evolved within the same environment, at a
molecular level, they are distinct. These differences are likely to
have contributed to the successful expansion of Clade 2 after its
reintroduction and the continued persistence of the ST239 clone
in this region. These differences also explain some of the pheno-
typic variation detected in Australian ST239 MRSA.
Changing phenotype of Australian ST239 MRSA. We took
advantage of the 32-year time span of ourAustralian ST239MRSA
culture collection to identify changes in clinically relevant pheno-
types (see Fig. S2 in the supplemental material).
Enhanced antimicrobial resistance. Reduced glycopeptide
susceptibility has been commonly reported in Australian MRSA
FIG 2 Genomic characterization of Australian ST239 clades. (A) Bayesian Skyline models illustrating the change in the EPS of Clades 1 (blue) and 2 (red). The
cladesweremodeled separately, and their EPSswere overlaid onto a single graph. Themedian EPS is indicated by the central white line, and the 95%HPD interval
is indicated by the colored zone. (B) MDS plot, based on protein ortholog clusters, illustrating the variation in gene content among the Australian isolates from
Clades 1 (blue) and 2 (red). Dim, dimension.
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isolates (15, 20). Intermediate-level resistance to vancomycin
(vancomycin-intermediate S. aureus [VISA]) and teicoplanin was
detected at low levels in our collection (15 and 3%, respectively).
However, a further 19 isolates (21%) were identified as heteroge-
neous VISA (hVISA), indicating that more than a third (36%) of
the collection had reduced glycopeptide susceptibility. Further-
more, daptomycin nonsusceptibility was detected in 15 isolates
(17%). These proportions, although consistent with previous es-
timations of hVISA and VISA in our region (15), may be an over-
representation due to the inclusion of a subset of isolates (n 24)
with known phenotypes of reduced susceptibility or nonsus-
ceptibility to these agents. They have therefore been excluded
from the following analyses of antimicrobial susceptibility and
bacterial fitness.
A comparison of antimicrobial susceptibility over time and
between phylogenetic clades is presented in Table 1. These analy-
ses demonstrated that the average MIC of vancomycin, teicopla-
nin, and daptomycin for isolates recovered after 1990 was signif-
icantly higher than that for those isolates recovered during the
1980s (P 0.003 to0.001). A comparison of the average MICs
for Clades 1 and 2 also showed a statistically significant difference,
with Clade 2 consistently having a higher average MIC of all three
antibiotics (P  0.016 to 0.001). As Clade 2 contained only
isolates recovered after 2000 and could therefore be creating a bias
in the comparison of older and newer isolates, the comparison of
temporal groups was repeated by testing Clade 1 independently of
Clade 2. While there appeared to be a trend of increasing MICs of
all three antibiotics (see Fig. S3 in the supplemental material),
consistent with the shift observed in the wider data set, a statisti-
cally significant increase was only detected in the average MIC of
daptomycin for Clade 1 isolates recovered after 1990 (P 0.013),
the P values for vancomycin and teicoplanin MICs being low but
nonsignificant (P 0.121 and 0.057, respectively).
There has been significant debate in the literature regarding
“MIC creep” in S. aureus (21). Previous studies, while demon-
strating increasing MICs for MRSA isolates over time, have not
performed detailed genotyping to determine if the isolates being
tested are related or not. Here, we provide an example of both
phenomena contributing to “MIC creep” in oneMRSA clone in a
single region, adaptive evolution within a clade and the introduc-
tion of a new clade, resulting in high rates of VISA infections
associated with enhanced morbidity and poor treatment re-
sponses (20, 22, 23).
GWAS. To identify the genetic mediators of enhanced antimi-
crobial resistance, in particular to vancomycin, a genome-wide
association study (GWAS) approach was implemented. These
types of studies often require large numbers of isolates to detect
associations, as the significance threshold is adjusted to account
for multiple testing (critical P value, 0.05/n). Therefore, it was
unsurprising that an initial comparison of the frequency of all of
the core genome SNPs resulting in nonsynonymous amino acid
changes between isolates with vancomycin MICs of 2 and
3 g/ml (Fig. 3A) failed to detect any significant associations.
Interestingly, the smallestP value achieved in this analysis was that
of an SNP resulting in an RpoBH481Y amino acid substitution (P
0.00029). This exact mutation within the beta subunit of the RNA
TABLE 1 Comparison of the antimicrobial susceptibility and bacterial fitness of temporal and phylogenetic groupsa
Group (no. of isolates tested)
MIC in g/mL
Bacterial
Fitness
Vancomycin Teicoplanin Daptomycin
Doubling Time
(mins)
Isolates recovered during 1980s (19) 1.09 0.81 0.24 39.35
Isolates recovered after 1990 (44) 1.45 1.49 0.51 45.62
P 0.003 P< 0.001 P< 0.001 P< 0.001
Phylogenetic Clade 1 (38) 1.18 0.97 0.35 43.90
Phylogenetic Clade 2 (25) 1.59 1.79 0.52 43.46
P< 0.001 P< 0.001 P 0.021 P 0.790
Clade 1 isolates recovered during 1980s (19) 1.09 0.81 0.24 39.35
Clade 1 isolates recovered after 1990 (19) 1.28 1.17 0.50 48.46
P 0.121 P 0.057 P 0.013 P< 0.001
a Each value is the mean result of the respective group. P values were determined with a Welsh two-sample t test with log transformations applied to MIC data prior to comparison.
FIG 3 GWAS of reduced vancomycin susceptibility in ST239 MRSA. Man-
hattan plots illustrate the results of two GWASs comparing isolates with van-
comycin MICs of 2 or 3 g/ml. The red line indicates the threshold of
significance (P value of0.05/number of hypotheses tested), as determined by
chi-square analysis. (A) Manhattan plot illustrating the associations between
SNPs and vancomycin MICs. The single red data point represents the SNP
resulting in anRpoBH481Y amino acid substitution. (B) SecondManhattan plot
illustrating the associations of CDSs containing a SNP(s), independent of the
SNP location within the locus, with vancomycin MICs. Highlighted red data
points represent the walK and walR genes, the only significant associations
identified in this analysis.
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polymerase has previously been demonstrated to lead to reduced
vancomycin susceptibility by using genetic manipulation experi-
ments (24) and was also identified in a recent GWAS of reduced
glycopeptide susceptibility (25). In the Australian ST239 collec-
tion, this SNP was identified in three phylogenetically dispersed
isolates with high vancomycin MICs. Furthermore, this analysis
revealed a high number of SNPs within the essential two-
component regulator walKR, all with very low P values (P 
0.00069).
To identify whether walKR, or any other gene, is a hot spot for
mutations associated with increased vancomycin MICs, a modi-
fied GWAS was performed. In this analysis, each CDS was classi-
fied as either “unaffected” or “affected”, the latter being assigned if
a SNP was identified within the locus, regardless of its location.
The frequencies of “affected” CDS in the same MIC groups de-
scribed above were then compared (Fig. 3B). This showed that
variant sequences of both walK and walR were highly associated
with increased vancomycinMICs (P 2.721 109 and 2.149
108, respectively). However, the exact mutations were highly
variable, with three different walR mutations identified in four
isolates and seven different walK mutations identified in seven
isolates (see Table S1 in the supplemental material). The DNA
sequences of rpoB and walKR are highly conserved in S. aureus;
however, mutations in both loci have previously been linked to
not only enhanced glycopeptide resistance (26) but also altera-
tions in virulence and, in the case of rpoB, resistance to the host
innate immune responses (27). The selective pressures driving
resistance to last-line antimicrobials in Australian ST239 MRSA
are therefore also likely to be having an impact on the fitness and
virulence of this clone.
Relative bacterial fitness.To determinewhether there has also
been a change in the relative fitness of Australian ST239 MRSA,
the average replication rate of each isolate was measured (see
Fig. S2 in the supplemental material). The mean doubling time of
the Australian collection (n 87) was 46.51 8.48 min or 43.73
 6.61 min when the subset of isolates (n  24) with known
resistance phenotypes was excluded. This finding is similar to the
previously published replication rate of five Australian ST239 iso-
lates of 42.2  6.5 min (28). A comparison of older and newer
isolates identified a statistically significant increase in the mean
doubling time of isolates recovered after 1990 (P  0.001) (Ta-
ble 1). This increase was also observed among newer Clade 1 iso-
lates when they were tested independently (P 0.001). No signif-
icant difference between the mean doubling times of Clades 1 and
2 was observed. However, Clade 2 isolates did demonstrate a sig-
nificantly slower replication rate thanClade 1 isolates recovered in
the 1980s (P  0.017) but a significantly faster rate than those
recovered after 1990 (P  0.008). This suggested that reduced
fitness among Australian ST239 MRSA was largely due to an in-
crease in the replication rate of Clade 1. Furthermore, Clade 2,
while demonstrating enhanced antimicrobial resistance, has not
suffered the same loss of fitness, another possible contributor to its
successful establishment within the Australian health care envi-
ronment.
Evolution to attenuated virulence but preserved in vivo per-
sistence in ST239 MRSA. Reduced virulence has been demon-
strated in HA-MRSA clones, particularly those that are multidrug
resistant (29–31); however, the evolution of virulence over time
has not been investigated. To determine the impact of hospital
adaptation on the virulence of Australian ST239MRSA, the activ-
ity of the accessory gene regulator (agr), the primary global viru-
lence regulatory system in S. aureus, wasmeasured, and the results
were confirmed in a murine infection model.
-Hemolysin production. The activity of the agr complex
was assessed by determining the phenotypic production of
-hemolysin (32). Of the 87 isolates in the collection, 40 (46%)
demonstrated -hemolysis and were thus considered to have an
active agr locus. The remaining 47 (54%) did not demonstrate
-hemolysis and were therefore considered agr defective. A com-
parison of agr activity and the year of isolation showed a dramatic
shift in the proportion of isolates with an active agr system over
time. Nearly 84% (16/19) of the isolates recovered during the
1980s appeared to have an active agr locus. However, this dropped
to 52% (12/23) of the isolates recovered between 1998 and 2002
and 31% (11/36) of those recovered between 2003 and 2007. All of
the isolates recovered after 2007 appeared to be agr defective, al-
though this time frame has been sparsely sampled. This suggests
strong selection pressure against agr activity in the Australian
health care environment and is consistent with the recent work of
Paulander et al. (33) in which exposure to selected antimicrobials
resulted in increased agr expression and reduced bacterial fitness.
They proposed that certain antibiotics may be indirectly driving
the selection of agr-defective isolates by imposing an RNAIII-
associated fitness cost on isolates with functional loci. When the
agr activities of the phylogenetic clades were compared, it became
apparent that all Clade 2 isolates were potentially agr defective.
When Clade 2 is excluded, a decrease in agr activity over time is
still observed, the percentage of Clade 1 isolates with an active agr
locus dropping from84% to 75% (12/16) and then to 52% (11/21)
for the pre-1990, 1998-to-2002, and 2003-to-2007 time frames,
respectively.
Reduction of agr activity is most commonly associated with
mutations in the agrABCD locus (32, 34). In the ST239 Australian
collection, only eight SNPs and two single base insertions were
identified within agrABCD but only seven of these resulted in
nonsynonymous amino acid changes (see Table S2 in the supple-
mentalmaterial). Intriguingly, a total of 37 isolates were identified
with a defective agr system but there was nomutation in agrABCD
to explain the loss of function. When the presence of agrABCD
mutation was compared to our regional phylogeny, it became ap-
parent that the most common SNPs, resulting in predicted
AgrCR6S and AgrCR393C changes, were found only within Clade 1
isolates (see Fig. S2 in the supplemental material). The predicted
AgrCR6S change was identified in all Clade 1 isolates, regardless of
agr activity. Alternatively, the AgrCR393C change was identified in
a subset of five isolates, all agr defective and all belonging to a
single subclade of Clade 1. The majority of the isolates that we
observed with a defective agr system and no agr mutations iden-
tified belonged to Clade 2.
RNAIII expression. To confirm these findings, reverse
transcription-quantitative PCR was performed with a subset of
isolates randomly selected from three groups, Clade 1 isolates re-
covered during the 1980s, Clade 1 isolates recovered after 1990,
and Clade 2 isolates. RNAIII expression among the representative
Clade 1 isolates revealed a dramatic reduction in the expression of
the agr complex over time (Fig. 4A), consistent with the findings
of the -hemolysin assay. Isolates recovered in the 1980s showed
very high RNAIII expression, often above that of the strong posi-
tive control JKD6159, a highly virulent ST93 community MRSA
isolate from Australia that produces large amounts of
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-hemolysin (35), a product positively regulated by RNAIII. The
discovery of isolates with expression levels higher than that of
JKD6159 suggested that early ST239 isolates were potentially
highly virulent but extended evolution within the hospital envi-
ronment has led to less virulent phenotypes. Of these 12 isolates,
only one produced a result inconsistent with the -hemolysin as-
say. BPH2070 showed no -hemolysis but expressed RNAIII at
low levels. This suggests that a negative result in the initial
-hemolysis screen may be indicative of both negative and very-
low-level RNAIII expression. Of the four Clade 1 isolates that did
not express RNAIII, only BPH2095 had an agr mutation that
could account for the loss of activity, carrying a single base inser-
tion within agrC resulting in a reading frameshift. No Clade 2
isolates demonstrated -hemolysis; however, four of the five rep-
resentative isolates expressed RNAIII at low levels, much like
BPH2070. The single Clade 2 isolate (BPH2016) that did not ex-
press RNAIII carried a single point mutation with a predicted
AgrCP24S amino acid change. These results suggest that most
Clade 2 isolates that do not possess an agrABCD mutation may
express RNAIII at low levels. Furthermore, it highlights that at
least three different mechanisms are contributing to attenuated
virulence in the ST239 clone,mutationwithin the locus disrupting
its activity, as well as external factors leading to both complete
inactivity and reduced RNAIII expression.
In vivo sepsis model. To determine whether Australian ST239
MRSA was indeed evolving toward attenuated virulence, eight of
the 12 Clade 1 isolates, four from each temporal group, tested for
RNAIII expression were also assessed in an in vivo murine sepsis
model. As the reduction in RNAIII expression over time was ob-
served only in Clade 1, Clade 2 isolates were not tested in this
model. The results of the in vivo murine sepsis model demon-
strated that Clade 1 isolates recovered in the 1980s were signifi-
cantly more virulent (Fig. 4B), in terms of both survival (P 
0.0054) and weight loss at day 2 (P  0.001), day 3 (P  0.046),
FIG 4 Evolution of ST239 MRSA toward attenuated virulence. (A) Fold changes in RNAIII expression levels compared to control JKD6159, as determined by
reverse transcription-quantitative PCR. Bar color indicates activity of the AGR complex as determined by the delta-hemolysin assay (black, active; grey, inactive).
Colored boxes below isolate names indicate those isolates that were tested in the in vivomurine sepsis model; colors represent the temporal groups to which they
belong (see panel B). (B) Results obtained with the in vivo sepsismodel. (Left) Seven-day survival curves grouped by year of isolation as indicated in the key. Each
group represents four bacterial isolates, each tested in 16 animals. The P value is for a comparison of Kaplan-Meier curves with a log-rank test. (Right) Bacterial
burdens in the kidneys at 7 days postinjection. Each data point represents one animal infected with one isolate. The detection threshold is shown by the grey line;
only values above this level are displayed.
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and day 4 (P  0.0056), compared to newer clade 1 isolates (see
Fig. S4 in the supplemental material), confirmation of the evolu-
tion of this clade toward attenuated virulence. Additionally, it has
been well demonstrated that RNAIII expression contributes to
virulence (35). Consistent with this, when isolates were regrouped
on the basis of RNAIII expression, those with high-level expres-
sion were more virulent in the murine model than isolates with
moderate or no RNAIII expression, as shown by both survival
(P 0.0027) and weight loss at day 2 (P 0.0001) and day 4 (P
0.0434) (see Fig. S4 in the supplemental material). Interestingly,
there appeared to be no difference in virulence between isolates
with moderate RNAIII expression and those with no RNAIII ex-
pression. The regulation of virulence in S. aureus is multifactorial,
and these results could indicate that lower-level RNAIII expres-
sion may be insufficient in these isolates for the transcriptional
regulation of downstream virulence determinants. Alternatively,
isolates with defective agr loci may have compensatory mecha-
nisms of pathogenesis that are independent of agr and have not
been explored in this study.
Previous studies have shown that isolates with attenuated vir-
ulence are capable of persistent infection (27), with a viable bac-
terial cell count detectable in the kidneys at 7 days postinjection in
a murine sepsis model. We also noted that our isolates were capa-
ble of persistence; however, it was not associated with a specific
phenotypic group (Fig. 4B). Our results suggest that ST239MRSA
is capable of persistent infection regardless of its relative virulence
level or evolutionary age.
Conclusions. Using detailed genomic and phenotypic analy-
ses, this study has revealed a very clear picture of the localized
evolution of one of the most important global clones of HA-
MRSA. The high resolving power of bacterial genomics has un-
covered a previously unrecognized reimportation of ST239MRSA
into Australia, perpetuating the ST239 epidemic in our region,
and demonstrated the genomic diversity between the cocirculat-
ing clades. Changes common to these two independent clades
have revealed an adaptation toward increased antimicrobial resis-
tance and a HA-MRSA clone that is primed for higher-level gly-
copeptide and daptomycin resistance. The apparent cost of these
changes has been a significant reduction in the replication rate and
virulencemeasured by analysis of doubling times, agr activity, and
a murine sepsis model. However, these changes may actually rep-
resent coselected adaptive advantages, as the capacity of the ST239
clone to cause persistent invasive infection remains significant.
These results shed new light on the complex evolution of S. aureus
clones that predominate within the health care environment and
illustrate how projects utilizing both comparative genomic and
functional approaches are essential to understanding the impact
of current antibiotic usage polices on hospital pathogens.
MATERIALS AND METHODS
Bacterial isolates. This study utilized a temporal and geographically dis-
persed collection of 123 ST239 S. aureus isolates. The culture collection
consisted of 87 isolates recovered from the Australia-New Zealand region
between 1980 and 2012. For genomic analyses, this collection was supple-
mented with the genome sequences of an additional 35 isolates from the
international collection of Harris et al. (10). Relevant isolate demograph-
ics are available in Data Set S1 in the supplemental material.
Genome sequencing and analyses.Of the Australian isolates, 71 were
sequenced in this study with MiSeq (Illumina) and a read length of 2 
150 bp. The genome sequence reads of previously published strains are
available under the following accession numbers: TW20, GenBank acces-
sion no. FN433596; the 35 international ST239 strains, Sequence Read
Archive accession no. ERA000102; JKD6008, GenBank accession no.
CP002120. Genomic and phylogenetic analyses were performed as de-
scribed in Text S1 in the supplemental material.
Phenotypic analyses. The experimental methodology and analysis of
antimicrobial susceptibility, growth rate, functionality of the agr locus and
the in vivo murine sepsis model are described in Text S1 in the supple-
mental material. All animal studies were performed in accordance with
the Animal Research Ethics Committee at the University of Melbourne.
Nucleotide sequence accession number. The sequence reads deter-
mined in this study were submitted to the European Nucleotide Archive
(ENA) under study number ERP009308, and can be accessed via http://
www.ebi.ac.uk/ena/data/view/ERP009308.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at http://mbio.asm.org/
lookup/suppl/doi:10.1128/mBio.00080-15/-/DCSupplemental.
Text S1, PDF file, 0.3 MB.
Data Set S1, PDF file, 0.1 MB.
Figure S1, PDF file, 0.03 MB.
Figure S2, PDF file, 0.1 MB.
Figure S3, PDF file, 0.1 MB.
Figure S4, PDF file, 0.1 MB.
Table S1, PDF file, 0.1 MB.
Table S2, PDF file, 0.1 MB.
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